Fig. 6

Immune cell deconvolution of AML biallelic CEBPA patients, TCGA-AML and BEAT patients. (A) CD200 expression (log2 normalized) in CEBPA mutated patients and WT patients in BEAT and TCGA cohorts. P-values from Wilcoxon rank sum test. (B) Deconvolution results of the RNA-seq data from 13 AML cases with biallelic CEBPA (top left panel), TCGA-AML CEBPA-mutated patients (top center panel) and TCGA-AML CEBPA WT (top right panel), BEAT CEBPA-mutated patients (bottom left panel) and BEAT CEPBA-WT (bottom right panel). Cell type proportions are shown in the y axis. Samples were clustered with euclidean distance and complete method. (C) Cell types with significantly different proportions between CEBPA-mutated and CEBPA-WT in the meta-analysis of the TCGA and BEAT cohorts. Random effects models p-value: B cells naive (p-value = 0.0867), B cells memory (p-value = 3.53E-5), dendritic cells activated (p = 0.0117) and Monocytes (p-value = 0.074). Meta-analysis plots can be found in Suppl. Figure 4.1. (D) Correlation of CD200 expression (log2 normalized) with B cells naïve and memory. Pearson correlation coefficient (R) and p-values are shown separately for CEBPA mutated and WT patients